GSK and Vir Biotechnology’s influenza research collaboration, established three years ago, has come to an end following the termination of their partnership. This decision was made after the Phase 2 failure of VIR-2482, an antibody targeted at preventing seasonal influenza A illness. Vir retains the rights to the antibodies and plans to seek other partners for further development. Despite this setback, Vir is pursuing partnerships for their next-generation influenza programs, including VIR-2981, which is expected to have an investigational new drug application filed with the FDA in the next 12 to 24 months. Additionally, Vir’s internal pipeline includes drug candidates for chronic hepatitis and HIV prevention, as well as a next-generation Covid antibody. The company reported having $1.6 billion in cash and investments as of the end of 2023.
Source link
GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact
